- Home
- RWAY vs GALT Comparison
RWAY vs GALT Comparison
Compare RWAY & GALT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | RWAY | GALT |
|---|---|---|
| Founded | 2015 | 2000 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | | Biotechnology: Pharmaceutical Preparations |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 284.1M | 297.0M |
| IPO Year | 2015 | 2008 |
Fundamental Metrics
Financial Performance| Metric | RWAY | GALT |
|---|---|---|
| Price | $6.95 | $3.43 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 6 | 2 |
| Target Price | ★ $9.50 | $8.50 |
| AVG Volume (30 Days) | ★ 566.5K | 376.1K |
| Earning Date | 05-07-2026 | 05-15-2026 |
| Dividend Yield | ★ 21.54% | N/A |
| EPS Growth | N/A | ★ 36.84 |
| EPS | N/A | ★ N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $1.26 | N/A |
| Revenue Next Year | $1.25 | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $5.19 | $2.03 |
| 52 Week High | $10.92 | $7.13 |
Technical Indicators
Market Signals| Indicator | RWAY | GALT |
|---|---|---|
| Relative Strength Index (RSI) | 73.96 | 49.65 |
| Support Level | $6.60 | $2.74 |
| Resistance Level | $6.97 | $4.35 |
| Average True Range (ATR) | 0.18 | 0.26 |
| MACD | 0.16 | -0.01 |
| Stochastic Oscillator | 98.12 | 81.82 |
Price Performance
Historical ComparisonAbout RWAY Runway Growth Finance Corp.
Runway Growth Finance Corp is a specialty finance company focused on providing senior secured loans to high-growth-potential companies in technology, life sciences, healthcare information and services, business services, select consumer services and products, and other high-growth industries. The company has Investments in the United States, Germany, and UK, Canada, Netherlands, with the majority of its portfolio invested in the United States. The company's investment objective is to maximize its total return to its stockholders through current income on its loan portfolio, and secondarily through capital gain on its warrants and other equity positions.
About GALT Galectin Therapeutics Inc.
Galectin Therapeutics Inc is a clinical-stage biopharmaceutical company. The company focuses on drug research and development to create new therapies for fibrotic disease, cancer, and selected other diseases. Its galectin-3 inhibitor is belapectin (GR-MD-02), which has been demonstrated in preclinical models to reverse liver fibrosis and cirrhosis.